Back to search results

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Abroad (travel likely)RecruitingPHASE1, PHASE2

Conditions

Amyotrophic Lateral Sclerosis (ALS) · Mutation in the Superoxide Dismutase-1 (SOD1) Gene

Simple summaryAI-assisted

This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.

Locations

  • Concord Repatriation General Hospital, Concord, New South Wales, Australia

  • Macquarie University, Sydney, New South Wales, Australia

  • Sunshine Coast University Hospital, Birtinya, Queensland, Australia

  • KU Leuven, Leuven, Vlaams-Brabant, Belgium

  • University of Alberta Hospital, Edmonton, Division of Neurology, Edmonton, Alberta, Canada

  • University Hospital - London Health Sciences Centre, London, Ontario, Canada

  • Sunnybrook Research Institute, Toronto, Ontario, Canada

  • Montreal Neurological Institute and Hospital, Montreal, Quebec, Canada

  • Hokkaido University Hospital, Sapporo, Hokkaido, Japan

  • Tokushima University Hospital, Tokushima, Tokushima, Japan

  • Toho University Omori Medical Center, Ōta-ku, Tokyo, Japan

  • Kyoto University Hospital, Kyoto, Japan

  • Hanyang University Seoul Hospital, Seoul, South Korea

  • Seoul National University Hospital, Seoul, South Korea

  • Noorlands University Hospital-Department of Neurology, Umeå, Noorland, Sweden

  • Kaohsiung Chang Gung Memorial Hospital, Kaohsiung City, Taiwan

  • Taipei Veterans General Hospital, Taipei, Taiwan

Study leads

  • Clinical Trial Management

    Study Director

    Regeneron Pharmaceuticals

View source on ClinicalTrials.gov(opens in a new tab)